Pharsight

1. List of Elestrin drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7198801	MYLAN SPECIALITY LP	Formulations for transdermal or transmucosal application	Jun, 2022 (7 months ago)

Market Authorisation Date: 15 December, 2006

Treatment: NA

Dosage: GEL, METERED;TRANSDERMAL

Strength	Dosage	Availability
0.06% (0.87GM/ACTIVATION)	GEL, METERED;TRANSDERMAL	Prescription

2. List of Evamist drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6978945	PADAGIS US	Dispensing device	Jul, 2022 (5 months ago)

Market Authorisation Date: 27 July, 2007

Treatment: NA

Dosage: SPRAY;TRANSDERMAL

Strength	Dosage	Availability
1.53MG/SPRAY	SPRAY;TRANSDERMAL	Prescription

3. List of Imvexxy drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11497709	THERAPEUTICSMD INC	NA	Nov, 2032 (9 years from now)
US10537581	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11246875	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11241445	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US10835487	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US9289382	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US10806697	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11351182	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US11304959	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Nov, 2032 (9 years from now)
US10888516	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US11123283	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US10668082	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US10568891	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US10471072	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Jun, 2033 (10 years from now)
US11116717	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US11065197	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Jun, 2033 (10 years from now)
US10398708	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (10 years from now)
US10258630	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Dec, 2033 (10 years from now)
US9180091	THERAPEUTICSMD INC	Soluble estradiol capsule for vaginal insertion	Dec, 2033 (10 years from now)
US11266661	THERAPEUTICSMD INC	Vaginal inserted estradiol pharmaceutical compositions and methods	Feb, 2034 (11 years from now)

Market Authorisation Date: 29 May, 2018

Treatment: Treatment of dyspareunia; Treatment of a symptom of vulvar and vaginal atrophy; Treatment of moderate to severe dyspareunia

Dosage: INSERT;VAGINAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
4 mcg and 10 mcg	30 Dec, 2019	1		20 Dec, 2033

Strength	Dosage	Availability
0.004MG	INSERT;VAGINAL	Prescription
0.01MG	INSERT;VAGINAL	Prescription

4. List of Minivelle drug patents

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9724310	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (5 years from now)
US8231906	NOVEN	Transdermal estrogen device and delivery	Jul, 2030 (7 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833419	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (5 years from now)
US9730900	NOVEN	Transdermal estrogen device and delivery	Jul, 2028 (5 years from now)

Market Authorisation Date: 29 October, 2012

Treatment: A method for administering estradiol comprising a monolithic transdermal drug delivery system consisting of (i) a backing layer and (ii) a single adhesive polymer matrix layer as claimed in us patent no. 9730900

Dosage: FILM, EXTENDED RELEASE;TRANSDERMAL

Strength	Submission Date	ANDA(s) Filed	First applicant approval	Last patent expiry	180 day status
0.0375 mg/day 0.05 mg/day 0.075 mg/day 0.1 mg/day	18 Aug, 2014	1	15 Aug, 2018	04 Jul, 2030	Deferred
0.025 mg/day	08 May, 2015	1	15 Aug, 2018	04 Jul, 2030	Deferred

Strength	Dosage	Availability
0.025MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.0375MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.05MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.075MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription
0.1MG/24HR	FILM, EXTENDED RELEASE;TRANSDERMAL	Prescription

5. List of Vagifem drug patents

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7018992	NOVO NORDISK INC	Hormone composition	Sep, 2022 (4 months ago)